Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy

Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy

The PI3K/AKT/mTORC1 pathway is a major therapeutic target for many cancers, particularly breast cancer. Everolimus is an mTORC1 inhibitor used in metastatic estrogen receptor-positive (ER+) and epidermal growth factor receptor 2-negative (HER2-) breast cancer. However, mTORC1 inhibitors have limited...

Full description

Bibliographic Details
Main Authors: Leslie Cuellar-Vite, Kristen L. Weber-Bonk, Fadi W. Abdul-Karim, Christine N. Booth, Ruth A. Keri
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
triple negative breast cancer
TNBC
mTORC1
FAK
focal adhesion kinase
rapamycin
Online Access:https://www.mdpi.com/2072-6694/14/14/3374

Internet

https://www.mdpi.com/2072-6694/14/14/3374

Similar Items